National Registry of eosinophilic oesophagitis
Eosinophilic Oesophagitis Registry - The Oesophageal section of the British Society of Gastroenterology has set up a National Registry of eosinophilic oesophagitis, to determine the frequency of this condition in Britain, to study its epidemiology and to encourage research into its patho-physiology and treatment. As you know, eosinophilic oesophagitis is being increasingly recognised in recent years and presents with food bolus obstruction, dysphagia and heartburn in adults, and regurgitation, food refusal and abdominal pain in children. Endoscopic changes have been described but the diagnosis is a histological one, based on eosinophilic infiltration of the oesophageal mucosa, > 15 or 20 per high power field, more than is normally found in gastro-oesophageal reflux disease.
We suspect eosinophilic oesophagitis may be under-diagnosed. We have put up a notice regarding the setting up of this Registry on the BSG website, and are also e-mailing members of the Pathological Society of Great Britain and Ireland and ENT UK. We would also like to draw your attention to this condition, to remind you to refer patients who present with dysphagia, food impaction and atypical or resistant reflux symptoms for endoscopy and oesophageal biopsies even if the oesophageal mucosa appears macroscopically normal. We would also ask that you enter all cases of eosinophilic oesophagitis into the Registry.
Data may be entered without the need for a log-in.
One of the priorities of the CSSC is improving access to treatment for patients with acute and chronic GI problems arising from cancer treatments. I would be most grateful if you would complete a short questionnaire on your local service to establish the current service provision in the UK.
The link below will take you to the survey in addition to links to BSG Guidance on the management of GI problems arising as a result of treatment for cancer and to a Resource Pack prepared by Lesley Smith, Consequences of Treatment Project Manager, DH National Cancer Survivorship Initiative.